Ijudo IV infusion 300mg, from AstraZeneca, contains Tremelimumab (genetical recombination). This monoclonal antibody is an immune checkpoint inhibitor that blocks CTLA-4, thereby promoting T cell activation and enhancing the immune system’s attack on tumors. It is supplied as 300mg in 15mL per bottle, with YJ code 4291465A2026.
Ijudo IV infusion 300mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →